Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Feb 13, 2015- New Therapy Demonstrated a Dramatic Improvement in Progression-Free Survival and a Statistically Significant Overall Response Rate in Some Patients with RAI-Refractory Differentiated Thyroid Cancer
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) approved the company's receptor tyrosine kinase inhibitor LENVIMA™ (lenvatinib) for the treatment of locally recurrent...
- Feb 13, 2015
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for BANZEL® (rufinamide) as an adjunctive treatment of seizures...
-
Feb 12, 2015FOR U.S. MEDIA ONLY
Results from the pivotal Phase 3 SELECT (Study of (E7080) LEnvatinib in Differentiated Cancer of the Thyroid) trial evaluating the use of investigational agent lenvatinib in the treatment of...
- Jan 20, 2015Eisai Launches New Savings Card to Increase Access and Affordability of BELVIQ® (lorcaserin HCl) CIVCard Enables Eligible Patients to Pay No More than $75 for their BELVIQ Prescription*
Eisai Inc. today announced the launch of a new savings card for BELVIQ® (lorcaserin HCl) CIV, the most prescribed branded FDA-approved prescription drug therapy for chronic weight management.**...
-
Jan 15, 2015•The European Prevention of Alzheimer’s dementia (EPAD) Initiative is a collaborative research initiative to improve the chance of successfully preventing Alzheimer’s dementia and to better understand early aspects of Alzheimer’s disease before dementia develops.
Paris, January 15, 2015 – The members of the EPAD initiative today announced the start of a novel collaboration between academic and private sectors to test innovative treatments for the...
- Dec 5, 2014-- Results of Investigational Studies of Perampanel and Rufinamide Accepted as Late-Breaking Posters --
Eisai Inc. announced today that 16 abstracts highlighting new data on perampanel and rufinamide will be presented at the 68th Annual American Epilepsy Society (AES) meeting, taking place in...
-
Dec 1, 2014FOR U.S. MEDIA ONLY
Eisai announced the presentation of six abstracts at the 2014 San Antonio Breast Cancer Symposium (SABCS), highlighting new data for eribulin mesylate and netupitant/palonosetron (NEPA). The...
-
Nov 17, 2014
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that Eisai has been ranked 11th among the world's leading pharmaceutical companies in the Access to Medicine Index...
- Nov 6, 2014Celebrity Animal Behaviorist Brandon McMillan Joins Eisai, Epilepsy Foundation and 4 Paws for Ability to Shed Light on How Dogs Can Provide Functional and Emotional Support
Eisai Inc. today announced the launch of Magnolia™ Paws for Compassion™, a new program created to raise awareness of the beneficial impact that animals can have on people living with epilepsy...
-
Nov 6, 2014-- Lorcaserin Evaluated for Effect on the NASH Clinical Score: A Retrospective Analysis of Three Phase 3 Studies --
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that data from the Phase 3 clinical trial program for lorcaserin HCl will be presented at the Annual Meeting of the...
